OrbiMed’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

OrbiMed’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,000	Closed	-$5.14M	–	146
2023 Q2	$5.14M	Hold	50,000	–	–	0.09%	102
2023 Q1	$5.46M	Buy	+50,000	New	+$5.53M	0.11%	103

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

OrbiMed's HZNP Position: Q4 2023 in Review

OrbiMed sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 266,400 shares — an estimated $30.8M sold.

OrbiMed first reported a position in HZNP in Q1 2014 and held it in 22 quarters. The position peaked at $289M in Q1 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

OrbiMed reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 266,400 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $30.8M.
OrbiMed first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 22 quarters.
OrbiMed's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $289M in Q1 2021.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.